Naloxone
Approved · EMAAlso known as 1-N-Allyl-14-hydroxynordihydromorphinone, Bunavail, Buprenorphine-Naloxone, Evzio+15 more
1-N-Allyl-14-hydroxynordihydromorphinone, Bunavail, Buprenorphine-Naloxone, Evzio, Kloxxado, Narcan, Rextovy, Rezenopy, Suboxone, Talwin NX, Targiniq ER, Zimhi, Zubsolv, (-)-naloxone, Nalossone, Naloxona, Naloxone Hydrochloride, Naloxone Hydrochloride Dihydrate, Naloxonum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
Opioid Antagonism in Hypogonadotropic Hypogonadism
Pilot Study of a Multi-System Analysis of Opioid Receptor Binding
Opioid use disorder: current trends and potential treatments.
Nucleus accumbens D1/D2 circuits control opioid withdrawal symptoms in mice.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression… Show full indicationShow less
Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Neural Correlates of Hypoalgesia Driven by Observation
Opioid Antagonism in Hypogonadotropic Hypogonadism
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Anesthesiology1
- COPD1
- Frontiers in public health1
- The Journal of clinical investigation1
- Transplantation1
- Baird JC1
- Blum K1
- Dahan A1
- Dang W1
- Dhar R1
- Florian J1
- Fu X1
- Fuehrlein BS1
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions1
- Brigham and Women's Hospital1
- Center for Drug Evaluation and Research1
- Center for Sports1
- College of Forensic Science1
- Dartmouth Medical School1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Naloxone in the shared literature.
Studied across the same disease area as Naloxone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.